AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04912635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neo App
Description: Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
Study NCT03402165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
Description: Response to DAAD's and developing HCC
Study NCT04230954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG oral once a day
Description: Cabozantinib 40 mg oral once a day
Study NCT04230954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks
Description: Pembrolizumab 200 mg IV every 3 weeks
Study NCT01678924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 given as injections into the area of pain on Day 1.
Study NCT01678924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-214868 Placebo (Vehicle)
Description: AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
Study NCT01122043 — intervention group
Intervention type: DEVICE
Intervention: Endoglide
Description: Device
Study NCT04117217 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Labs drawn
Description: We will collect blood samples/biomarkers at the time of enrollment.
Study NCT01946971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Study NCT01946971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00303381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 44 microgram
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
Study NCT00303381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
Study NCT00303381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 66 microgram
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Study NCT04537585 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tomeka®
Description: Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
Study NCT04537585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernonia amygdalina
Description: Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity).
Study NCT00569335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Irinotecan, Bevacizumab
Description: S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA >1.25 to \<1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1.
Study NCT02135094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy device
Description: low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
Study NCT02135094 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound therapy device
Description: The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
Study NCT03720522 — intervention group
Intervention type: PROCEDURE
Intervention: Short cardiovascular MRI (CMR)
Description: A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Study NCT03720522 — intervention group
Intervention type: PROCEDURE
Intervention: Adenosine-perfusion cardiovascular MRI (CMR)
Description: An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Study NCT01682837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
Study NCT03720522 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Study NCT03720522 — intervention group
Intervention type: PROCEDURE
Intervention: Urine (collection over 24h)
Description: The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months
Study NCT01682837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium magnesium citrate powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
Study NCT02410031 — intervention group
Intervention type: DRUG
Intervention: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
Description: Cyproterone acetate 2mg/ethinylestradiol 35 μg
Study NCT01674959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks).
Study NCT04075188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
Study NCT04442373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: 1.8 ml blood sample
Study NCT00665717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40 mg tablet; QD; 4 days
Study NCT00665717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg tablet; BD 4 days
Study NCT00665717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin and raltegravir
Description: pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
Study NCT01125436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
Study NCT01125436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: Weekly placebo plus 800 calcium alone
Study NCT01598389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding study
Description: In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
Study NCT01788137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (CHOP)
Description: Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
Study NCT01788137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy(c-ATT)
Description: Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
Study NCT02674074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared thermography
Description: measurement of corneal temperature by infrared thermography before and after cold provocation
Study NCT01040676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone Nutrition Support
Description: See Intervention Group description.
Study NCT03047473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: add on of avelumab 10mg/kg IV to standard therapy
Study NCT04229277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: optical coherence tomography
Description: comparison of four imaging technologies in skin tumour diagnosis
Study NCT05147285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stabilization exercises
Description: Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
Study NCT05147285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined exercises
Description: Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
Study NCT05147285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Description: The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
Study NCT00902291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-1C4D4
Description: IV infusion
Study NCT00902291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT00902291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT02677675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (reminder module)
Description: Reminder module (delivered via SMS and telephone call reminders)
Study NCT02996370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: papilla fill index
Description: The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
Study NCT02996370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crestal bone loss
Description: Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
Study NCT02996370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: probing depth
Description: The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
Study NCT02996370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified sulcus bleeding index
Description: Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
Study NCT00754130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
Study NCT02996370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified plaque index
Description: Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
Study NCT03252574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A
Description: AIR+ Smart Mask Only
Study NCT03252574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: B
Description: AIR+ Smart Mask with micro-ventilator
Study NCT04816422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Description: rocedure~1. Bilateral upper extremity pattern for trunk by Chopping, Lifting~2. Bilateral lower extremity pattern for trunk.~3. Trunk lateral flexion.~4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
Study NCT04816422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability.
Study NCT03178019 — intervention group
Intervention type: OTHER
Intervention: Laser-Doppler methods
Description: This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
Study NCT01682837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
Study NCT01296152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depo-medroxyprogesterone acetate
Description: At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
Study NCT01964898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
Study NCT01964898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Smoking Cessation Counseling
Description: 1 hour of in hospital counseling based on clinical guidelines
Study NCT01964898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Counseling
Description: 1 hour of in hospital counseling based on clinical guidelines
Study NCT01964898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
Study NCT01964898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
Study NCT01964898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Self-help materials for Smoking Cessation
Study NCT03577119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Full-fat yogurt
Description: Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
Study NCT03577119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fat yogurt
Description: Controlled diet that includes three daily servings of fat-free yogurt.
Study NCT03180983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multimodal intervention
Description: Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
Study NCT02014649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg laninamivir octanoate
Study NCT02014649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02014649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg laninamivir octanoate
Study NCT02889536 — intervention group
Intervention type: OTHER
Intervention: Focus group interviews
Description: Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
Study NCT02233881 — intervention group
Intervention type: DRUG
Intervention: Atrovent® - inhalets
Study NCT02641171 — intervention group
Intervention type: OTHER
Intervention: Specimen sampling
Description: exhaled air samples blood samples fecal samples
Study NCT00479765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OncoGel (ReGel/Paclitaxel)
Description: OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
Study NCT02294552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02294552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT02294552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Study NCT02294552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02294552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02294552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Study NCT02971332 — intervention group
Intervention type: PROCEDURE
Intervention: Stapled Transanal Rectal Resection
Description: The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure.
Study NCT03952663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve lateralization and dental implant placement.
Description: inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
Study NCT03952663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior alveolar nerve lateralization and dental implant placement.
Description: inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
Study NCT03952663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin membrane around the nerve
Description: platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
Study NCT01283373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTP3086S
Description: DSTP3086S administered intravenously
Study NCT01283373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTP3086S
Description: Escalating intravenous dose
Study NCT04742816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IHX-CL measurements
Description: The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
Study NCT04742816 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Iohexol clearance measurement